Kazia Therapeutics Limited (KZA:ASX)


right-arrow Created with Sketch. -0.01 (-0.78%)
MCAP $169.0M
Last trade 16.10pm 28/07/2021 20mins delayed

Latest Announcements

30/06/2021KZAKazia Therapeutics Limited
24/06/2021 Price SensitivePSKZAKazia Therapeutics Limited
21/06/2021KZAKazia Therapeutics Limited
15/06/2021 Price SensitivePSKZAKazia Therapeutics Limited
07/06/2021 Price SensitivePSKZAKazia Therapeutics Limited
02/06/2021KZAKazia Therapeutics Limited
27/05/2021KZAKazia Therapeutics Limited
21/05/2021KZAKazia Therapeutics Limited

Company Overview

Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.

KZA in the news

Search Previous Announcements